# Medicare drug price negotiation for 2028: apalutamide, ribociclib, abemaciclib and lenvatinib

Source: https://onco.cc/terms/medicare-negotiation-2028-cancer-drugs/  
OnCo record `medicare-negotiation-2028-cancer-drugs` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Four cancer medicines are among the drugs selected for the third round of Medicare price negotiation, with prices due from 1 January 2028: Erleada (apalutamide), Kisqali (ribociclib), Verzenio (abemaciclib) and Lenvima (lenvatinib). The negotiated prices had not been published in CMS's data file by November 2026.

## Summary

United States, Medicare Drug Price Negotiation Program, third cycle. CMS's data file of 2 November 2026 lists fourteen drugs for initial price applicability year 2028, each with an effective date of 1 January 2028. Four are cancer medicines: Erleada (apalutamide), Kisqali (ribociclib), Verzenio (abemaciclib) and Lenvima (lenvatinib). The file gives no maximum fair price for any 2028 drug yet; the price columns are blank.

## Fields

- Kind: Term
- Last checked: 2026-11-04
- Also known as: IPAY 2028; third cycle of Medicare drug price negotiation; Erleada negotiation; Kisqali negotiation; Verzenio negotiation; Lenvima negotiation
- Tags: law; us

## Notes

- The census counted 15 drugs for 2028 from a CMS fact sheet; the data file of 2 November 2026 lists 14. The record states what the file shows.
- No 2028 price was in the file on 4 November 2026; none is stated.

## Sources

- CMS: Negotiation Program selected drug list and maximum fair price data file, 2 November 2026 (ZIP): https://www.cms.gov/files/zip/cms-negotiation-program-selected-drug-list-maximum-fair-price-data-file-20261102.zip
- CMS: Medicare Drug Price Negotiation Program: https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program

## Connected records

- terms: [Inflation Reduction Act 2022: Medicare drug price negotiation](https://onco.cc/terms/inflation-reduction-act/), [Medicare negotiated price for ibrutinib (Imbruvica), first cycle](https://onco.cc/terms/medicare-negotiation-2026-cancer-drug/), [Medicare negotiated prices from 2027: enzalutamide, pomalidomide, palbociclib and acalabrutinib](https://onco.cc/terms/medicare-negotiation-2027-cancer-drugs/)
- drugs: [Abemaciclib](https://onco.cc/drugs/abemaciclib/), [Apalutamide](https://onco.cc/drugs/apalutamide/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/), [Ribociclib](https://onco.cc/drugs/ribociclib/)
- bottlenecks: [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/)

---
JSON: https://onco.cc/api/v1/entities/medicare-negotiation-2028-cancer-drugs.json